Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
14.14
+0.56 (4.12%)
Dec 20, 2024, 4:00 PM EST - Market closed
Zymeworks Employees
As of December 31, 2023, Zymeworks had 278 total employees, including 272 full-time and 6 part-time employees. The number of employees decreased by 16 or -5.44% compared to the previous year.
Employees
278
Change (1Y)
-16
Growth (1Y)
-5.44%
Revenue / Employee
$223,737
Profits / Employee
-$408,888
Market Cap
973.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
Owens & Minor | 22,200 |
HealthStream | 1,092 |
Vir Biotechnology | 587 |
Bicycle Therapeutics | 284 |
Collegium Pharmaceutical | 197 |
Avadel Pharmaceuticals | 154 |
ZYME News
- 2 days ago - Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule - Seeking Alpha
- 4 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - GlobeNewsWire
- 6 weeks ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - GlobeNewsWire
- 6 weeks ago - Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab - Seeking Alpha
- 7 weeks ago - Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewsWire
- 2 months ago - Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers - GlobeNewsWire